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The transcription factor T-bet directs Th1 cell differ-
entiation, but the molecular mechanisms that under-
lie this lineage-specific gene regulation are not
completely understood. Here, we show that T-bet
acts through enhancers to allow the recruitment of
Mediator and P-TEFb in the form of the super elonga-
tion complex (SEC). Th1 genes are occupied by
H3K4me3 and RNA polymerase II in Th2 cells, while
T-bet-mediated recruitment of P-TEFb in Th1 cells
activates transcriptional elongation. P-TEFb is re-
cruited to both genes and enhancers, where it
activates enhancer RNA transcription. P-TEFb inhibi-
tion and Mediator and SEC knockdown selectively
block activation of T-bet target genes, and P-TEFb
inhibition abrogates Th1-associated experimental
autoimmune uveitis. T-bet activity is independent
of changes in NF-kB RelA and Brd4 binding, with
T-bet- and NF-kB-mediated pathways instead
converging to allow P-TEFb recruitment. These
data provide insight into the mechanism through
which lineage-specifying factors promote differenti-
ation of alternative T cell fates.
INTRODUCTION
The differentiation of T helper cells into specialized effector line-
ages is a powerful model for understanding how master regu-
lator transcription factors establish cell identity. Upon encounter
with antigen, naive T cells can differentiate into one of several
effector lineages (Zhu et al., 2010). The paradigm for the study
of the T helper cell fate choice is the differentiation into either
Th1 or Th2 lineages. Th1 cells activate cell-mediated immunity,
essential to combat viral and intracellular bacterial infection,
while Th2 cells orchestrate a humoral response to parasites.2756 Cell Reports 15, 2756–2770, June 21, 2016 ª 2016 The Author(
This is an open access article under the CC BY license (http://creativeInappropriate Th1 and Th2 responses are associated with auto-
immunity and allergy, respectively. A degree of plasticity also
exists between the different lineages and this may allow the im-
mune response to be tuned as environmental cues vary (Murphy
and Stockinger, 2010; O’Shea and Paul, 2010).
CD4 T cell fate choice is governed by a set of lineage-speci-
fying transcription factors, which are activated differentially de-
pending on the cytokine environment (Zhu et al., 2010). T-bet is
necessary and sufficient for Th1 cell differentiation (Lazarevic
et al., 2013; Szabo et al., 2000). How T-bet promotes Th1 differ-
entiation has primarily been determined through the study of Ifng.
T-bet activates Ifng by binding at the gene itself and to multiple
enhancer elements spanning a 146 kb region up and down-
stream (Balasubramani et al., 2010; Hatton et al., 2006; Schoen-
born et al., 2007; Shnyreva et al., 2004). T-bet has been reported
to be necessary for recruitment of the NF-kB family member
RelA (Balasubramani et al., 2010), the Setd7 H3K4 methyltrans-
ferase complex, and the H3K27 demethylase Kdm6b (Jmjd3;
Miller et al., 2008) to Ifng, but the extent to which T-bet utilizes
thesemechanisms across the genome is unknown. T-bet also re-
cruits p300 to the Ifng locus, but across the genome, only 17%of
p300 binding sites in Th1 cells are dependent on T-bet, suggest-
ing that it has a limited role in establishing the binding pattern of
this co-factor (Vahedi et al., 2012).
Analysis of T-bet binding across the mouse and human ge-
nomes has revealed hundreds of immune regulatory genes at
which T-bet binds across extended cis-regulatory regions similar
to that at Ifng (Kanhere et al., 2012; Nakayamada et al., 2011; Zhu
et al., 2012). Although T-bet binds to the promoters of thousands
of genes, it only functions at the subset of genes associated with
these extended regulatory regions (Kanhere et al., 2012).
Similar regions of dense transcription factor binding have been
identified in a number of cell types and termed super-enhancers
(Brown et al., 2014; Chapuy et al., 2013; Di Micco et al., 2014;
Hnisz et al., 2013; Love´n et al., 2013; Whyte et al., 2013), tran-
scription initiation platforms (Koch et al., 2011), or stretch en-
hancers (Parker et al., 2013). Super-enhancers are defined
computationally as genomic regions that display unusually highs).
commons.org/licenses/by/4.0/).
levels of occupancy of a transcription factor or co-activator.
Super-enhancers share similarities with locus control regions
characterized by functional studies (Smith and Shilatifard,
2014), and genes associated with super-enhancers tend to be
cell-type specific (Hnisz et al., 2013; Koch et al., 2011; Parker
et al., 2013; Whyte et al., 2013). Thus, super-enhancer definition
provides a useful tool for identifying a set of candidate regulatory
loci important for the identity of the cell. As such, p300 binding
has been used to identify super-enhancers and genes specific
to Th1, Th2, and Th17 lineages (Vahedi et al., 2015).
In embryonic stem cells (ESCs), regions defined as super-en-
hancers are highly occupied by the co-activatorsMediator, CBP,
and p300, the BET protein Brd4, cohesin, and the Lsd1-NuRD
complex (Hnisz et al., 2013; Whyte et al., 2013; Di Micco et al.,
2014). The high levels of Brd4 binding at activated oncogenes
in cancer cells (Chapuy et al., 2013; Love´n et al., 2013) and at
proinflammatory genes in endothelial cells (Brown et al., 2014)
and T cells (Peeters et al., 2015) renders them hyper-sensitive
to transcriptional repression by BET-inhibitors, providing a po-
tential therapeutic route for cancer and inflammatory diseases.
However, the mechanisms by which T-bet functions at en-
hancers to activate Th1 gene expression are still unclear.
Using a combination of primary human T cells and mouse
models, we report here that Th1 genes undergo transcriptional
initiation in Th1 and Th2 cells and that T-bet activates Th1 genes
through recruitment of Mediator and the super elongation com-
plex, with Brd4 instead recruited in a parallel pathway dependent
on NF-kB.
RESULTS
Transcriptional Initiation at Th1 and Th2 Genes in the
Opposing Cell Lineage
We hypothesized that profiling total RNA pol II occupancy by
chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq)
in human Th1 and Th2 cells would provide insight into how
T-bet functions to regulate gene expression. We first defined
Th1 and Th2 genes as those expressed differentially across mul-
tiple samples, as done previously (see Wei et al., 2011; Hawkins
et al., 2013; Stubbington et al., 2015). As expected, plotting
ChIP-seq read density across Th1 genes in Th1 cells revealed
occupancy of RNA pol II at transcription start sites (TSS), which
increased upon restimulation (Figures 1A, 1E, and S1A–S1C;
Table S1). RNA pol II was also present at Th1 genes in Th2 cells,
albeit at a reduced level. Similarly, RNA pol II occupied Th2
genes in both Th1 and Th2 cells (Figures 1A, 1E, and S1A–
S1C). Comparison of RNA pol II levels across Th1 genes be-
tween restimulated Th1 and Th2 cells revealed an increasing
difference across the gene body, suggesting greater elongation
efficiency in Th1 cells (Figure 1B). A corresponding effect was
observed for Th2 genes, with RNA pol II showing increased elon-
gation efficiency in Th2 cells (Figure 1B).
We sought to confirm transcriptional initiation of Th1 and Th2
genes in both lineages bymeasuring the initiation marker histone
H3 trimethylated at lysine 4 (H3K4me3) in cells polarized for
extended periods of time (28 days; Figures 1C, 1E, S1D, and
S1E; Table S1). As we found for RNA pol II, H3K4me3 was pre-
sent at Th1 and Th2 genes in both cell lineages. This was alsoapparent using an independent previously defined set of human
Th1 and Th2 genes (Hawkins et al., 2013) (Figure S1G) and inmu-
rine Th1 and Th2 cells using our own and previously defined Th1
and Th2 gene sets (Wei et al., 2011; Stubbington et al., 2015) and
our own and previously acquired H3K4me3 ChIP-seq data (Wei
et al., 2009) (Figures S1H–S1J). To test whether this phenome-
non also occurred in cells polarized in vivo, we performed
ChIP-seq for H3K4me3 in human CCR5+ Th1 memory cells.
This revealed the presence of H3K4me3 at both Th1 and Th2
genes in these cells, showing that this finding was not an artifact
of in vitro polarization (Figures 1D, S1F, and S1G). Taken
together with our RNA pol II binding data, these results show
that transcription is initiated at Th1 and Th2 genes in both Th1
and Th2 cells and suggests that differential expression is primar-
ily a function of differences in transcriptional elongation.
Recruitment of P-TEFb to Th1 Genes and Super-
Enhancers
We have previously shown that T-bet regulates gene expression
by binding to multiple distal sites at extended cis-regulatory re-
gions (Kanhere et al., 2012). We sought to determine whether
these regions also fall into the definition of super-enhancers. Anal-
ysisof replicateT-betChIP-seqexperimentsusing theROSEalgo-
rithm (Hnisz et al., 2013) identified 374 super-enhancers in human
Th1 cells (Figures S2A and S2B; Table S2). As expected, T-bet
super-enhancers were associatedwith high levels of H3K27 acet-
ylation (FigureS2C), CD4+T cell-specific expression (FigureS2D),
and functions related to the immune response (Figure S2E).
We next considered how T-bet function may be linked to line-
age-specific transcriptional elongation and hypothesized that dif-
ferential recruitment of the elongation factor P-TEFb may be
involved. ChIP-seq for P-TEFb revealed increased recruitment
in activated Th1 cells to genes with T-bet super-enhancers (Fig-
ures 2A, 2B, and S2F). In contrast, RNA pol II occupancy was
similar at genes associated with super-enhancers and typical
enhancers and was also comparable between Th1 and Th2 cells.
Indeed, geneswith super-enhancers exhibited significantly higher
P-TEFb occupancy at their start sites compared to other active
genes, even when considering the level of RNA pol II occupancy
(p < 2 3 1016 [K-S (Kolmogorov-Smirnov) test]; Figure S2G).
In addition to binding at genes, we unexpectedly found that
P-TEFb also bound extensively to intergenic sites, with 35% of
sites located outside of genes (Figures 2B and 2C), double that
of RNA pol II (17%) and also greater than the active enhancer
mark H3K27ac (24%). In intergenic regions, P-TEFb was local-
ized to T-bet binding sites associated with H3K27ac (Fig-
ure S2H), with P-TEFb exhibiting particularly extensive binding
at T-bet super-enhancers (Figures 2B and 2D). Indeed, 75% of
genes associated with P-TEFb at the TSS and at an intergenic
site were T-bet targets, compared with only 6% of genes where
P-TEFb occupied the TSS only. The binding of P-TEFb to inter-
genic sites appeared to be functionally important; genes
occupied by P-TEFb at the TSS and an intergenic site were over-
expressed in Th1 cells relative to Th2 cells (Figure 2E). Further-
more, genes occupied by P-TEFb at the TSS and an intergenic
site were enriched for functions related to the immune response,
whereas, in comparison, genes only occupied by P-TEFb at the
TSS had functions in cell metabolism and translation (Figure 2F).Cell Reports 15, 2756–2770, June 21, 2016 2757
A E
B
C
D
Figure 1. Transcriptional Initiation at Th1 and Th2 Genes in Both Lineages
(A) Average number of ChIP-seq reads for RNA pol II (reads/million) across Th1 genes (left) and Th2 genes (right) in unstimulated (US) or restimulated (RS) human
Th1 and Th2 cells.
(B) Log2 ratio ofRNApol II acrossTh1genes (left) andTh2genes (right) betweenRSTh1andTh2cells. Thedifference inRNApol II levels increasesacross thegenes.
(C) As in (A), except for H3K3me3 in Th1 and Th2 cells polarized for an extended period of time.
(D) As in (A), except for H3K4me3 in CCR5+ Th1 memory cells.
(E)ChIP-seqbindingprofiles forRNApol II andH3K4me3atexampleTh1genesandTh2genes in in vitropolarizedTh1andTh2cells and inCCR5+Th1memorycells.
See also Figure S1.These data suggest that Th1 genes are regulated in a distinct
manner involving P-TEFb recruitment to enhancers.
Th1 Genes Are Hyper-Sensitive to Inhibition of
Elongation
The high-level of P-TEFb binding at Th1 and Th2 genes argues
that the switch from transcriptional initiation to elongation is a2758 Cell Reports 15, 2756–2770, June 21, 2016particularly critical control point in the expression of these genes.
To test this, we measured gene expression in in vitro differenti-
ated mouse Th1 and Th2 cells in the presence of the P-TEFb in-
hibitor Flavopiridol or the BET inhibitor JQ1, which inhibits
P-TEFb recruitment (Brown et al., 2014; Chapuy et al., 2013; Di
Micco et al., 2014; Love´n et al., 2013). We found that Th1 gene
expression was significantly reduced by Flavopiridol and JQ1
A 
B 
F 
D 
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(legend on next page)
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Figure 3. Th1 Genes Are Hyper-Sensitive to
Inhibition of Transcriptional Elongation
(A) Cumulative distribution frequency of gene
expression changes in Th1 cells treated with
DMSO, Flavopiridol (10 mM), or JQ1 (500 nM)
relative to naive T cells. The genes are divided
into Th1 genes (n = 291) or all expressed genes
(n = 8,095). DFlav(all) = 0.17, p < 2.2 3 10
16;
DFlav(Th1) = 0.39, p < 2.2 3 10
16; DJQ1(all) = 0.053,
p = 1.94 3 1010; and DJQ1(Th1) = 0.13, p = 0.011
(K-S test).
(B) As in (A), except for Th2 genes (n = 228) or
all expressed genes (n = 8,095) in Th2 cells.
DFlav(all) = 0.13, p < 2.2 3 10
16; DFlav(Th2) = 0.26,
p = 2.39 3 107; DJQ1(all) = 0.054, p = 1.02 3
1010; and DJQ1(Th2) = 0.155, p = 0.92 3 10
3
(K-S test).
(C) Expression changes of genes in Th1 cells in
response to Flavopiridol versus DMSO control.
Genes with typical T-bet enhancers (blue,
n = 1,561), T-bet super-enhancers (red, n = 270),
or neither (black, n = 6,264) are shown. DTyp =
0.081, p = 1.21 3 107; DSuper = 0.22, p = 9.54 3
1012; and DTyp_vs_Super = 0.16, p = 1.55 3 10
5
(K-S test).
(D) Scatterplot of changes in gene expression in
Th1 cells in response to Flavopiridol versus
changes in response to JQ1. The genes are
divided as in (C).
(E) Average ChIP-seq density for P-TEFb in human
Th1 cells across all genes, genes repressed by
both Flavopiridol and JQ1 (n = 232), and genes
only repressed by either Flavopiridol (n = 109) or
JQ1 (n = 128).
See also Figure S3.(Figures 3A and S3A). The effect of Flavopiridol was much
greater than that of JQ1, completely reversing the induction of
Th1 genes. In contrast, other genes exhibiting the same expres-
sion levels were not substantially affected by either drug (Figures
3A and S3B). Similar results were observed for Th2 genes (Fig-
ure 3B). Thus, consistent with their high-levels of P-TEFb bind-
ing, Th1 and Th2 genes are hyper-sensitive to inhibition of
transcriptional elongation compared to other expressed genes.
We next assessedwhether the sensitivity of Th1 genes to elon-
gation inhibition was related to super-enhancer function. We first
identified the set of T-bet super-enhancers in mouse Th1 cellsFigure 2. Extensive P-TEFb Binding at Super-Enhancers and Associat
(A) Average number of ChIP-seq reads for RNA pol II and P-TEFb in unstimulated (
pol II in at least one condition and divided into those associated with a super-en
(B) T-bet, P-TEFb, and RNA pol II binding at IFNG, CSF2 (associated with T-bet
(C) Percentage of sites for RNA pol II, H3K4me3, H3K27ac, and P-TEFb in Th1 c
(D) Distribution of T-bet and P-TEFb ChIP-seq signals across 3,191 T-bet Th1 en
super-enhancers are to the right of the vertical dashed line. The ChIP signals are
(E) Cumulative distribution frequency of gene expression in Th1 cells relative to Th
the TSS and an intergenic site (red, n = 245) (D = 0.19, p = 7.47 3 107 [K-S tes
(F) Significance of the enrichment of biological process gene ontology categories i
TSS and an intergenic site (red).
See also Figure S2.
2760 Cell Reports 15, 2756–2770, June 21, 2016using replicate T-bet ChIP-seq data (Figure S3C; Table S2).
Then, dividing genes into those associated with super-en-
hancers, typical enhancers, or neither, revealed that Flavopiridol
blocked expression of genes associated with super-enhancers,
but had little effect on those associated with typical enhancers
(Figure 3C). Thus, super-enhancers show a specific requirement
for P-TEFb to activate gene transcription.
Although JQ1 repressed a number of key Th1 genes (Fig-
ure S3E), the effect of JQ1 on Th1 gene expression was less strik-
ing than that of Flavopiridol (Figures 3D and S3E), suggesting that
Brd4 does not play such a major role at these genes. Indeed, JQ1ed Genes
US) or restimulated (RS) human Th1 and Th2 cells. All genes are bound by RNA
hancer (n = 231) or a typical enhancer (n = 1,307).
super-enhancers), and the housekeeping gene RPL13.
ells that are proximal (<2 kb from TSS), distal intragenic, or distal intergenic.
hancers, ranked according to T-bet signal. The enhancers classified as T-bet
shown as moving averages (window size of 100 bp).
2 cells for genes occupied by P-TEFb at the gene TSS only (blue, n = 970) or at
t]).
n the set of genes occupied by P-TEFb at the gene TSS only (blue) or at the gene
(legend on next page)
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and Flavopiridol had markedly different effects in Th1 cells, with a
Pearson correlation co-efficient of only 0.12 (Figure 3D). This was
also apparent with lower concentrations of each drug, indicating
that this was not a reflection of differential off-target effects (Fig-
ure S3D). Flavopiridol was more specific for P-TEFb target genes
than JQ1, as demonstrated by higher levels of P-TEFb binding at
genes specifically repressed by Flavopiridol (Figures 3E and
S3E; Table S3). These data suggest that Brd4 plays a relatively
minor role in the recruitment of P-TEFb to T-bet target genes.
T-bet Functions to Recruit P-TEFb to Genes and
Enhancers in Activated Th1 Cells
Given that P-TEFb bound with T-bet to super-enhancers and
associated genes, we next asked whether T-bet functioned in
the recruitment of P-TEFb. To test this, we first performed
ChIP-seq for P-TEFb in restimulated CD4+ T cells purified from
wild-type (WT) and T-bet/mice cultured under Th1 conditions.
We found that in the absence of T-bet, P-TEFb showed reduced
binding to super-enhancers and to their associated genes (Fig-
ure 4A). Thus, T-bet is necessary for the high levels of P-TEFb
recruitment observed at Th1 genes and enhancers.
To determine if T-bet was sufficient to recruit P-TEFb, we em-
ployed twomurine EL4 cell lines, one that stably expresses T-bet
and GFP and a control line expressing GFP alone (Kanhere et al.,
2012). ChIP-seq for P-TEFb in both cell lines showed that
P-TEFb occupancy increased at super-enhancers and their
associated genes when T-bet was present (Figure 4B). We could
also detect an interaction between T-bet and P-TEFb by co-
immunoprecipitation (Figures S4A–S4C), consistent with a role
for T-bet in P-TEFb recruitment. We conclude that T-bet func-
tions to allow recruitment of P-TEFb to super-enhancers and
associated genes in activated Th1 cells.
T-bet Is Necessary for Recruitment of Mediator and the
Super Elongation Complex
We next explored how T-bet functioned in the recruitment of
P-TEFb to super-enhancers and their associated genes.
P-TEFb can be recruited to genes through NF-kB (Barboric
et al., 2001), the BET domain protein Brd4 (Jang et al., 2005;
Yang et al., 2005), and by Mediator (Donner et al., 2010; Wang
et al., 2013), which recruits P-TEFb as part of the super elonga-
tion complex (SEC) (Takahashi et al., 2011).
To test whether these mechanisms were in operation at T-bet
super-enhancers, we measured the effect of T-bet expression inFigure 4. T-bet Is Necessary for Recruitment of Mediator, the SEC, an
(A) Scatterplot showing the read density (RPKM) for P-TEFb at super-enhancer-as
Th1 cells (left). A scatterplot showing the P-TEFb peak height (reads/million) at inte
Th1 cells is on the right.
(B) As in (A), except for activated EL4 cells stably expressing GFP (x axis) versus
(C) ChIP-seq binding profiles for T-bet, P-TEFb, RelA, Brd4,Med1, andAff4 in EL4 c
GFP,withbothcell lines restimulatedwithPMAand ionomycin.Thepositionsof trans
(D) As in (C), except for WT and T-bet/ Th1 cells restimulated with PMA and io
(E) Cumulative distribution frequency of the change in P-TEFb, Aff4, Med1, Brd4,
enhancers and associated genes (SE), at typical enhancers and associated gene
(F) Expression of Aff4 andMed1 and the T-bet target genes Furin, Dusp5, Xcl1, C
unstimulated and restimulated Th1 cells transduced with retroviruses encoding s
(G) As in (F), except for shRNAs to luciferase (white) or Med1 (green) (mean and
knock down of Med1 and Med17 is shown in Figure S4.
2762 Cell Reports 15, 2756–2770, June 21, 2016activated EL4 cells on the binding of RelA, Brd4, the Mediator
subunit Med1, and the core SEC component Aff4. First focusing
on Ifng, we found that T-bet induced binding of each protein to
the promoter and to multiple distal regulatory elements that sur-
round the gene (Figure 4C). To quantify the effect of T-bet on the
binding of each factor across the genome, we measured the
change in binding upon T-bet expression at all super-enhancers
and associated genes compared to the change in binding at
other sites across the genome and plotted the cumulative distri-
bution frequencies (Figures S4D and S4E; Table S4). This re-
vealed significant increases in P-TEFb, Aff4, Med1, and Brd4
occupancy at super-enhancers and their associated genes in
EL4 cells when T-bet was present (p < 0.05, Mann-Whitney
U test). Thus, we conclude that T-bet is sufficient for the recruit-
ment of P-TEFb, Aff4, Med1, and Brd4 in activated cells.
We then asked whether T-bet was necessary for the recruit-
ment of Aff4, Med1, Brd4, and RelA by measuring changes in
their binding between restimulated WT and T-bet/ cells
cultured under Th1 conditions. We also measured levels of the
transcriptional initiation marker H3K4me3, to monitor this stage
of gene activation. Comparing super-enhancers and their asso-
ciated genes with other sites, we noted a marked deficiency in
P-TEFb, Aff4, and Med1 recruitment in T-bet/ cells (p < 0.05,
Mann-Whitney U test; Figures 4D, 4E, and S4F; Table S5). In
contrast, recruitment of Brd4 and RelA were unaffected by
T-bet deletion (p > 0.05; Figures 4E and S4F). Thus, T-bet is
necessary for recruitment of Mediator and the SEC, but not for
Brd4 and RelA binding. Consistent with a lack of a direct role
for T-bet in RelA recruitment, a mutant form of T-bet (S508A),
which does not interact with RelA (Hwang et al., 2005), had no
effect on RelA binding at Ifng in EL4 cells (Figure S4G).
H3K4me3 levels at super-enhancers and associated genes
were also unaffected upon T-bet loss (Figure 4E), consistent
with the presence of H3K4me3 at Th1 genes in Th2 cells (Fig-
ure 1) and confirming that T-bet does not act through super-en-
hancers to regulate this stage of gene activation.
Although T-bet deletion did not cause significant changes
to Brd4 and RelA binding at super-enhancers compared to
other sites, some binding events, such as the Ifng 54, 34
kb, and promoter sites, were dependent on T-bet (Figure 4D).
To assess whether these T-bet-dependent sites were associ-
ated with P-TEFb recruitment, we identified the T-bet-depen-
dent sites for each factor and measured the changes in
P-TEFb binding at those locations (Figure S4H). We found thatd P-TEFb to Genes and Super-Enhancers
sociated genes occupied by P-TEFb in primarymouse T-bet+/+ versus T-bet/
rgenic T-bet binding sites (p < 109) in primary mouse T-bet+/+ versus T-bet/
cells stably expressing T-bet and GFP (y axis).
ells stably expressing GFP alone or EL4 cells stably expressing FLAG-T-bet and
cription factorbindingsites relative to the IfngTSSaremarked (to thenearest kb).
nomycin.
RelA, and H3K4me3 occupancy between T-bet/ and T-bet+/+ cells at super-
s (Typical), and at other sites (Other).
sf2, Ccl3, and Ccl4 relative to Hprt (mean and SD, n = 2 biological replicates) in
hRNAs against luciferase (white) or Aff4 (red).
SD, n = 3 technical replicates). A replicate experiment with combined shRNA
BC
A
Figure 5. NF-kB Is Necessary for P-TEFb Recruitment to T-bet Target Genes and Super-Enhancers
(A) ChIP-seq binding profiles for FLAG-T-bet and P-TEFb at the Ifng locus in EL4-GFP and EL4-T-bet cells with and without restimulation.
(B) ChIP-seq binding profiles for RelA, P-TEFb, Brd4, Med1, and Aff4 at the IFNG locus in human Th1 cells with and without treatment with BAY 11-7082 (20 mM).
(C) Average number of ChIP-seq reads for RelA, P-TEFb, Brd4, Med1, and Aff4 at T-bet super-enhancers in human Th1 cells with and without treatment with BAY
11-7082 (20 mM) (top). Cumulative distribution frequency of the change in transcriptional regulator binding (log2 BAY 11-7082 versus DMSO) for sites at super-
enhancers and associated genes (SE), typical enhancers and associated genes, and at other sites bound by each factor (bottom).
See also Figure S5.only T-bet-dependent recruitment of Med1 and Aff4 were asso-
ciated with changes in P-TEFb occupancy. Thus, changes in
Mediator and SEC binding, but not changes in Brd4 and RelA,
are associated with T-bet-dependent P-TEFb recruitment.
To confirm whether Mediator and the SEC were important for
the activation of T-bet target genes, we knocked down Med1
and Aff4 in mouse Th1 cells with small hairpin (sh)RNAs. We
found that the expression of T-bet target genes such as Ifng,
Furin, Xcl1,Csf2, Ccl3, andCcl4were downregulated compared
to the housekeeping gene Hprt (Figures 4F, 4G, S4I, and S4J).
We conclude that T-bet operates through the Mediator-SEC
pathway to allow recruitment of P-TEFb to super-enhancers
and associated genes.RelA Is Necessary for Recruitment of P-TEFb, Mediator,
Brd4, and the SEC to T-bet Target Genes
The ability of T-bet to recruit P-TEFb also requires cell restimula-
tion (Figures 2A, 2B, 5A, and S5A), suggesting that additional
factors were also necessary. In other cell types, RelA can recruit
P-TEFb to genes directly (Barboric et al., 2001), through Brd4
(Brown et al., 2014; Huang et al., 2009; Sharma et al., 2007), or
through Mediator (van Essen et al., 2009; Wienerroither et al.,
2015). In Th1 cells, RelA binds to, and is necessary for, activation
of Ifng (Balasubramani et al., 2010; Sica et al., 1997). However,
the role of NF-kB in P-TEFb recruitment and Th1 gene activation
across the genome is unknown. To address this, we first per-
formed ChIP-seq for RelA in human Th1 cells and found that itCell Reports 15, 2756–2770, June 21, 2016 2763
was associated with 75% of T-bet super-enhancers (Table S6).
We then treated human Th1 cells with the IkB kinase inhibitor
BAY 11-7082 and measured the change in RelA, P-TEFb,
Brd4, Med1, and Aff4 recruitment by ChIP-seq. We found that
IkB kinase inhibition significantly reduced the recruitment of all
of these factors and that super-enhancers and their associated
genes were particularly sensitive (p < 107, Mann-Whitney
U test; Figures 5B, 5C, and S5B). Thus, in addition to T-bet,
NF-kB has a central role in recruitment of the transcriptional
elongation machinery to T-bet target genes and super-en-
hancers across the genome. Furthermore, the lack of change
in RelA and Brd4 binding upon T-bet deletion (Figure 4E) indi-
cates that these pathways operate independently and converge
at super-enhancers to allow P-TEFb recruitment.
T-bet and P-TEFb Function at Super-Enhancers to
Activate Enhancer RNA Transcription
Given thatP-TEFbboundextensively at super-enhancersand this
was associated with increased requirement for P-TEFb function
(Figure 3C), we sought to determine whether P-TEFb plays a
role at super-enhancers themselves. In other cell types, some en-
hancers produce enhancer (e)RNAs that contribute to enhancer
function (Lamet al., 2014; Natoli and Andrau, 2012).We therefore
hypothesized that P-TEFb functioned at T-bet super-enhancers
in the production of eRNAs. To test this, we performed total and
poly-A+ RNA-seq in human Th1 and Th2 cells and, to control for
the increased size of super-enhancers, compared the numbers
of sequence reads around T-bet binding sites within intergenic
super-enhancers versus typical enhancers. We found that
eRNA transcription was higher at T-bet binding sites within su-
per-enhancers compared to those at typical enhancers (Figures
6A and S6A). Furthermore, eRNAs transcribed from T-bet su-
per-enhancers tended to be Th1-specific (Figures 6B and S6B).
At IFNG, eRNAs were transcribed in Th1 cells from the super-
enhancer upstream of the gene (Figures 6C and S6F); enhancers
downstreamof IFNG exhibited lower levels of P-TEFb occupancy
andeRNAproduction. IFNGeRNAsdisplayed featurespreviously
ascribed to eRNAs, being transcribed bidirectionally, unspliced,
and non-poly-adenylated (Figures 6C and S6F). eRNAs could
also clearly be observed at super-enhancers associated with
other key lineage-specific genes (Figure S6H; Table S7).
These data suggested that T-bet functions at super-en-
hancers to induce eRNA transcription. To test this, we measured
expression of Ifng eRNAs in Th1 and Th2 cells from T-bet/
mice by quantitative (q)PCR. We found that the level of each
eRNA tested was reduced in T-bet deficient cells, demonstrating
that T-bet acts to induce eRNA transcription (Figure 6D).We next
tested whether P-TEFb activity was required for Ifng eRNA pro-
duction. Treatment of Th1 cells with JQ1 and Flavopiridol re-
sulted in a marked reduction in eRNA levels, with Flavopiridol
having the strongest effect (Figure 6E). Thus, P-TEFb functions
at super-enhancers to activate eRNA transcription.
Suppression of T-bet Function and Uveitis by P-TEFb
Inhibition In Vivo
We sought to test the importance of P-TEFb in a Th1 response
in vivo through use of a mouse experimental autoimmune uveitis
(EAU)model, in which infiltration of interferon-g-producing CD4+2764 Cell Reports 15, 2756–2770, June 21, 2016T cells into the retina can be induced by immunization with inter-
photoreceptor retinoid-binding protein (IRBP) (Gardner et al.,
2013). IRBP peptide was administered and, after 8 or 9 days,
mice were treated with Flavopiridol (3 and 15 mg/kg) or JQ1
(3 and 30 mg/kg), and disease progression was scored by retinal
fundoscopy and histology (Agarwal et al., 2012; Gardner et al.,
2013). We found that both drugs significantly reduced disease
severity. Immunized mice treated with carrier alone displayed
severe EAU, characterized by disruption to retinal layers, diffuse
retinal detachment, and folding, intense cellular infiltration and
granulomatous lesions (histological score of 4; Figures 7A–7C
and 7J). In contrast, mice treated with Flavopiridol and JQ1
showed reduced disease, with average histological scores
between 1 and 2, minimal cell infiltration, and well-preserved
photoreceptor layers (Figures 7D–7J, S7A, and S7B). We then
sought to confirm that disease abrogation was reflected by a
reduction in the expression of super-enhancer-associated Th1
genes. Flow cytometric analysis of CD4+ T cells sorted from
the retina and lymph node revealed that expression of the su-
per-enhancer-associated gene products Ifng, Tnf, Fasl, Il18r1,
and Ctla4 were downregulated by Flavopiridol and JQ1 (Figures
7K, 7L, and S7C–S7G). We conclude that P-TEFb is required
for Th1 gene expression in vivo and for Th1 cell-mediated
immunopathology.
DISCUSSION
How T-bet regulates Th1 gene expression across the genome
has been unclear. We show here that Th1 and Th2 genes un-
dergo transcriptional initiation in a lineage-independent manner
and that T-bet acts through extended regulatory regions
(super-enhancers) to allow recruitment of Mediator and
P-TEFb in the form of the SEC to activate Th1 gene expression.
T-bet is necessary for P-TEFb recruitment, not just to gene pro-
moters, but to super-enhancers themselves, where it functions
to activate eRNA transcription. P-TEFb inhibition specifically
downregulates Th1 genes and alleviates pathology in a Th1
cell-dependent uveitis model. T-bet is not required for RelA or
Brd4 recruitment to most sites at Th1 genes. Instead, T-bet
and NF-kB-dependent pathways converge at super-enhancers
to allow P-TEFb recruitment. These data thus provide insight
into the mechanisms of T-bet function during Th1 lineage-spec-
ification in human and mouse.
Mediator is a large multi-subunit complex that integrates sig-
nals from multiple transcription factors to modulate transcrip-
tion, chromatin modification, and looping between promoters
and enhancers (Carlsten et al., 2013). It is particularly important
for transcription of genes related to cell type specification, but
has not previously been shown to play a role in transcription of
such genes in T cells. Mediator promotes transcriptional elonga-
tion by recruiting P-TEFb via Med23 (Wang et al., 2013) and the
CDK8 submodule (Donner et al., 2010) or as part of the SEC via
Med26 (Takahashi et al., 2011). The SEC allows rapid gene in-
duction in ESCs (Lin et al., 2013), thus it may perform a similar
role in CD4+ T cells.
Unlike other systems (Brown et al., 2014; Chapuy et al., 2013;
Di Micco et al., 2014; Love´n et al., 2013; Peeters et al., 2015),
T-bet does not operate by inducing large-scale changes in
A C 
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Brd4 binding. Instead, NF-kB activation is required for Brd4
recruitment in a parallel pathway. RelA has previously been
shown to be required for Ifng expression downstream of the
T cell receptor (TCR) (Balasubramani et al., 2010). We show
here that RelA occupies the majority of T-bet bound super-en-
hancers and associated genes and, like T-bet, is necessary for
recruitment of Mediator and the SEC, but is also necessary for
Brd4 recruitment. However, there is no significant loss of RelA
and Brd4 binding at T-bet super-enhancers and their associated
genes compared to other sites in T-bet/ cells. Thus, T-bet and
RelA operate through separate, but co-dependent pathways,
that converge at super-enhancers to allow recruitment of P-
TEFb to T-bet target genes. This model is consistent with the
ability of enhancer clusters to integrate inputs from multiple
signaling pathways (Spitz and Furlong, 2012) andmay constitute
a control mechanism to ensure that Th1 gene activation only oc-
curs when multiple immunological signals are received.
How lineage-specifying factors function to promote differenti-
ation toward a defined lineage, but also maintain the functional
plasticity observed between effector subtypes has been a key
unresolved issue. Epigenetic profiling has previously suggested
that the establishment of bivalent chromatin at key lineage-spe-
cific transcription factors may be important (Wei et al., 2009). Our
results reveal more generally that Th1 and Th2 genes remain
associated with RNA pol II and H3K4me3 in the opposing line-
age, and that T-bet acts to allow recruitment of Mediator and
the SEC to activate transcriptional elongation. This mechanism
may contribute to the functional plasticity observed between T
helper cell subtypes.
We identified extensive association of P-TEFbwith enhancers.
Brd4 (Brown et al., 2014; Chapuy et al., 2013; Di Micco et al.,
2014; Hnisz et al., 2013; Love´n et al., 2013; Zhang et al., 2012)
and the elongation factor Ell3 (Lin et al., 2013) have previously
been identified at enhancers, but the extent of P-TEFb binding
at these sites has not previously been observed. Our results
support the notion that P-TEFb functions at super-enhancers
to activate eRNA transcription. Th1 cell eRNAs share similarities
with those observed previously in other cell types, being pre-
dominantly non-poly-adenylated and transcribed bidirectionally
(Lam et al., 2014; Natoli and Andrau, 2012). Previous reports
disagree on whether eRNA production in other cell types re-
quires transcriptional elongation, but the loss of eRNAs upon
Flavopiridol and JQ1 treatment demonstrates that P-TEFb is
required for eRNA transcription in Th1 cells.
Our study into the mechanisms through which T-bet directs
Th1 lineage-specification suggests potential therapeutic ave-
nues. BET inhibitors have previously been used to repress tran-Figure 6. T-bet and P-TEFb-Dependent Production of Enhancer RNAs
(A) Average total RNA-seq density (reads/million) in restimulated (RS) human Th1
versus those within intergenic typical enhancers (n = 908).
(B) As in (A), except for Th2 cells (same scale as A) (top). As in (A), except for unsti
(C) Total RNA and mRNA-seq data (reads/million) at IFNG showing production
stimulated (RS) human Th1 cells. The read density at the IFNG gene extends beyo
(D) qRT-PCR for eRNAs (relative to Hprt, mean and SD, and n = 3 technical rep
stimulated (RS) Th1 and Th2 cells polarized for 48 hr or 7 days. The eRNAs are l
(E) As in (D), except for WT cells treated with 50 (+) or 500 nM (++) JQ1 (left) or t
See also Figure S6.
2766 Cell Reports 15, 2756–2770, June 21, 2016scriptional elongation in immune cells and protect against
inflammation in a number of models (Bandukwala et al., 2012;
Brown et al., 2014; Mele et al., 2013; Nicodeme et al., 2010; Pee-
ters et al., 2015). Although our experiments reveal a requirement
for BET domain proteins for Th1 gene expression, Flavopiridol
was the more selective for Th1 genes, consistent with the invari-
ance in Brd4 binding upon T-bet deletion. Thus, direct inhibition
of P-TEFb or Mediator may represent a more efficacious and
specific means of targeting Th1 genes for the treatment of in-
flammatory and autoimmune conditions.
EXPERIMENTAL PROCEDURES
Cells
Human and mouse naive T cells were isolated and cultured under Th1 and Th2
polarizing conditions for 13 days, as described (Kanhere et al., 2012). For
H3K4me3 ChIP-seq, cells were differentiated for 28 days. Human CCR5+
Th1 memory T cells were purified as described (Messi et al., 2003). EL4-GFP
and EL4-T-bet cells were described in Kanhere et al. (2012).
Mice
C57BL/6 mice were purchased from Charles River Laboratories International.
T-bet/ mice were purchased from Taconic. B10.RIII mice were obtained
from GlaxoSmithKline. Mice were housed at the KCL Biological Service
Unit (BSU) or at the UCL Institute of Ophthalmology BSU. Animal experi-
ments were performed in accordance with the UK Animals (Scientific Proce-
dures) Act 1986 (Home Office License Numbers PPL: 70/6792, 70/7869 and
70/7265).
ChIP-Seq
ChIP was performed as described (Kanhere et al., 2012), except H3K4me3
ChIP was performed on native chromatin. All antibodies used and data sets
generated are listed in the Supplemental Information. Libraries were con-
structed using standard Illumina protocols and were sequenced with an
Illumina GAIIx or HiSeq 2500. Reads were filtered to remove adapters using
fastq-mcf and for quality using seqkt and aligned to hg19 ormm9with Bowtie2
(default settings). Consistency between replicates was assessed by irrepro-
ducible discovery rate (IDR) analysis; in each case, Np/Nt was less than 2,
the standard reproducibility threshold used by the ENCODE project. Signifi-
cantly enriched regions were identified with MACS v1.4 using a p value
threshold of 107 unless indicated. Super-enhancers were identified with the
ROSE algorithm (Love´n et al., 2013; Whyte et al., 2013; Hnisz et al., 2013).
The significance of changes in transcription factor binding upon T-bet expres-
sion was assessed with a Mann-Whitney U test.
Microarray Analysis
Total RNA was labeled using the two-color Low Input Quick Amp Labeling Kit
and hybridized to SurePrint G3 DNA microarrays (Agilent). Differentially
expressed genes were identified by rank-sum test (pfp < 0.05). Murine
Th1 and Th2 genes and genes repressed by Flavopiridol and/or JQ1 were
identified by applying fold-change expression thresholds. The significance
of differences in expression between gene sets was assessed with a K-S test.cells at T-bet binding sites located within intergenic super-enhancers (n = 269)
mulated Th1 cells (middle). As in (A), except for mRNA in RS Th1 cells (bottom).
of non-poly-adenylated RNAs from the + (Watson) or  (Crick) strands in re-
nd the maximum y axis value. The ChIP-seq binding profiles are shown above.
licates) in WT and T-bet/ naive mouse T cells and unstimulated (US) or re-
abeled according to their position relative to the Ifng TSS.
reated with 1 (+) or 10 mM (++) Flavopiridol for 6 hr (right).
JK
L
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Strand-Specific RNA-Seq
Poly-adenylated RNA was isolated with Oliogtex (QIAGEN). rRNA was
depleted from total RNA with Ribo-Zero Gold (EpiCentre). Libraries were pre-
pared using the Illumina Directional mRNA-Seq Sample Prep and the NEBNext
Multiplex Small RNA Library Prep kits and then sequenced on an Illumina
HiSeq 2500. RNA-seq reads were filtered for quality and to remove adapters,
aligned to hg19 using TopHat2, and transcripts identified with Cufflinks v2.1.1
using default settings.
EAU
B10.RIII mice were immunized subcutaneously with 300 mg IRBP161–180
(Cambridge Peptides) and monitored by fundoscopy on days 8–9 (Agarwal
et al., 2012; Gardner et al., 2013). Flavopiridol (3 and 15 mg/kg) and
JQ1 (3 and 30 mg/kg) were administered by daily intraperitoneal injection
and disease progression scored by retinal fundoscopy and histology at
days 14–15. Enucleated eyes were fixed, sectioned, stained with eosin,
and counterstained with hematoxylin and graded (Agarwal et al., 2012).
Single cell suspensions were prepared from retinas or inguinal lymph
nodes for flow cytometry. The significance of changes in disease scoring
and in the number of cells expressing T-bet target genes were assessed
with a t test.
shRNA Knockdown
Naive mouse CD4+ T cells were activated under Th1 polarizing conditions and
transduced with pMY-Thy1.1-miR-30 retrovirus expressing shRNAs targeting
firefly luciferase, Aff4, Med1, or Med17. After 3 days, Thy1.1+ cells were
purified by magnetic cell sorting. On day 7, cells were either restimulated
with 2 mg/ml anti-CD3/CD28 for 6 hr or left unstimulated.
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